17 October 2023 Vigil Neuroscience Announces First Participant Dosed in Phase 1 Clinical Trial in Healthy Volunteers Evaluating VG-3927, a Small Molecule TREM2 Agonist, for Potential Treatment of Alzheimer’s Disease read more
13 October 2023 Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023 read more
11 October 2023 Quanta Therapeutics Presents Late-Breaking Data for QTX3034, a multi-KRAS inhibitor, at AACR-NCI-EORTC Conference read more
10 October 2023 Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer read more
27 September 2023 Avalyn Raises $175 Million in Oversubscribed Series C Financing to Advance Inhaled Pulmonary Fibrosis Programs into Later Stage Clinical Studies read more
